Bellicum Pharmaceuticals, Inc.
BLCM · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -98.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | – | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -0.1% | – | -108,062.5% | -1,469.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -76.3% | – | -93,587.5% | -1,239% |
| EPS Diluted | -0.025 | -0.24 | -0.24 | -0.2 |
| % Growth | 89.7% | 0% | -20% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |